Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mariaelena Capone

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
Cell Host & Microbe|October 31, 2024
Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patientsAngeli D G Macandog, Carlotta Catozzi, Mariaelena Capone, et al.
Med (New York, N.Y.)|January 24, 2023
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitorsNicolas Gonzalo Nuñez, Fiamma Berner, Ekaterina Friebel, et al.
Nature Medicine|June 5, 2025
Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanomaKelsey R Monson, Robert Ferguson, Joanna E Handzlik, et al.
Eclinicalmedicine|November 15, 2023
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Ahmed Shaheen, Charlotte Grieco, et al.
Eclinicalmedicine|April 4, 2024
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Ahmed Shaheen, Charlotte Grieco, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Cell Host & Microbe|October 31, 2024
Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patientsAngeli D G Macandog, Carlotta Catozzi, Mariaelena Capone, et al.
Med (New York, N.Y.)|January 24, 2023
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitorsNicolas Gonzalo Nuñez, Fiamma Berner, Ekaterina Friebel, et al.
Nature Medicine|June 5, 2025
Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanomaKelsey R Monson, Robert Ferguson, Joanna E Handzlik, et al.
Eclinicalmedicine|November 15, 2023
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Ahmed Shaheen, Charlotte Grieco, et al.
Eclinicalmedicine|April 4, 2024
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Ahmed Shaheen, Charlotte Grieco, et al.
Pageof 7